Autopsy report · NCT02958917

Study of Efficacy and Safety of Pirfenidone in Patients With Fibrotic Hypersensitivity Pneumonitis

“covid-19 pandemic”

The sponsor’s own words in the registry.

Life of this trial

• Registered 7 months before it started.
• Ran for about 3 years 9 months before it stopped.
• 40 participants enrolled.
• Results were posted on the registry 1 year 10 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Evans Fernandez Perez

Sponsor type

University, hospital or other

Conditions

Interstitial Lung Disease

Interventions

Pirfenidone; Placebo controlled

Participants

40

Sites

1

Countries

United States

Trials that died the same way

• Resting Energy Expenditure in Patients With OHS Treated With Long-term NIV
  “COVID pandemic” (90% match in meaning)
• Microbiome Alterations in IL10RA-deficient Patients After HSCT
  “COVID-19” (87% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.